The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Author:

Patel Hiten D1,Puligandla Maneka2,Shuch Brian M3,Leibovich Bradley C4,Kapoor Anil5,Master Viraj A6,Drake Charles G7,Heng Daniel YC8,Lara Primo N9,Choueiri Toni K10,Maskens Deborah11,Singer Eric A12,Eggener Scott E13,Svatek Robert S14,Stadler Walter M15,Cole Suzanne16,Signoretti Sabina17,Gupta Rajan T18,Michaelson Marc Dror19,McDermott David F20,Cella David21,Wagner Lynne I22,Haas Naomi B23,Carducci Michael A124,Harshman Lauren C10,Allaf Mohamad E1

Affiliation:

1. Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

2. Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

3. Department of Urology, Yale School of Medicine, New Haven, CT, USA

4. Department of Urology, Mayo Clinic, Rochester, MN, USA

5. Division of Urology, McMaster University, Hamilton, ON, Canada

6. Department of Urology, Emory University School of Medicine, Atlanta, GA, USA

7. Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA

8. Tom Baker Cancer Center, Calgary, AB, Canada

9. Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA

10. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

11. Kidney Cancer Canada, Toronto, Ontario, Canada

12. Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

13. Section of Urology, University of Chicago, Chicago, IL, USA

14. Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

15. Department of Medicine (Hematology/Oncology), University of Chicago, Chicago, IL, USA

16. Department of Medicine (Hematology/Oncology), University of Texas Southwestern Medical Center, Dallas, TX, USA

17. Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA

18. Departments of Radiology & Surgery & The Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA

19. Massachusetts General Hospital Cancer Center, Boston, MA, USA

20. Division of Hematology-Oncology & Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

21. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

22. Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA

23. Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, PA, USA

24. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Abstract

Patients with high-risk renal cell carcinoma (RCC) experience high rates of recurrence despite definitive surgical resection. Recent trials of adjuvant tyrosine kinase inhibitor therapy have provided conflicting efficacy results at the cost of significant adverse events. PD-1 blockade via monoclonal antibodies has emerged as an effective disease-modifying treatment for metastatic RCC. There is emerging data across other solid tumors of the potential efficacy of neoadjuvant PD-1 blockade, and preclinical evidence supporting a neoadjuvant over adjuvant approach. PROSPER RCC is a Phase III, randomized trial evaluating whether perioperative nivolumab increases recurrence-free survival in patients with high-risk RCC undergoing nephrectomy. The neoadjuvant component, intended to prime the immune system for enhanced efficacy, distinguishes PROSPER from other purely adjuvant studies and permits highly clinically relevant translational studies.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3